Compass Therapeutics
potential best in class agonist | Compass Therapeutics
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
17 of 23
Similar slides by Compass Therapeutics
See diffirences between slides (animation)
Investor Presentation
May 2023
potential best in class agonist | Compass Therapeutics
Investor Presentation
February 2023
potential best in class agonist | Compass Therapeutics
Related slides by other companies
Kymera
Investor Presentation
August 2023
part summary | Kymera
Nuvalent
Investor Presentation
January 2024
a rationally designed alk selective sparing inhibitor medical needs alk gen gen gen lin preliminary phase conclusions investigational gen alk activity alk single mutant activity alk compound mutant activity ens activity avoiding alk activity observed in patients with alk including after exhausting available therapies alk single mutant activity activity observed in patients with diverse single alk resistance mutations alk compound mutant activity activity observed in patients with diverse compound alk resistance mutations activity air avoiding activity observed in patients with history of including intracranial responses emerging safety profile was consistent with design key observed in clinical investigation source lin head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Checkmate Pharmaceuticals
IPO
August 2020
a differentiated agonist | Checkmate Pharmaceuticals
Chimerix
Investor Presentation
May 2023
agonist | Chimerix
Other recent decks by Compass Therapeutics
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
February 2023
Investor Presentation
January 2023
Investor Presentation
May 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights